What percentage of the time does minimal-risk emetogenic chemotherapy cause CINV?

Minimal-risk emetogenic chemotherapy is generally associated with a low incidence of chemotherapy-induced nausea and vomiting (CINV). In clinical practice, minimal-risk regimens lead to CINV occurrences in about 10% of patients. This data informs clinicians about the likelihood of CINV when considering antiemetic prophylaxis and managing patient expectations.

Understanding the risk levels associated with different chemotherapy agents is crucial, as it assists healthcare professionals in tailoring the supportive care provided to patients. Recognizing that minimal-risk chemotherapy results in CINV around 10% of the time emphasizes the importance of continuous monitoring and assessment, even in lower-risk groups.